Commons, Marty

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

First Posted Date
2006-03-13
Last Posted Date
2011-08-26
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT00302016
Locations
🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

Stroger Cook County Hospital, Chicago, Illinois, United States

🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

and more 56 locations

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

First Posted Date
2006-03-08
Last Posted Date
2012-08-16
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
721
Registration Number
NCT00300274
Locations
🇺🇸

Hahnemann University Hospital, Philadelphia, Pennsylvania, United States

🇺🇸

Temple University Hospital, Philadelphia, Pennsylvania, United States

🇺🇸

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

and more 61 locations

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

First Posted Date
2006-01-25
Last Posted Date
2023-02-10
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
444
Registration Number
NCT00281658
Locations
🇺🇦

Novartis Investigative Site, Zaporizhzhia, Ukraine

Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2006-01-20
Last Posted Date
2010-06-30
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
34
Registration Number
NCT00279773
Locations
🇺🇸

The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

First Posted Date
2006-01-09
Last Posted Date
2023-04-28
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
63
Registration Number
NCT00272987
Locations
🇧🇪

Novartis Investigative Site, Liege, Belgium

Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-01-09
Last Posted Date
2017-02-07
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
25
Registration Number
NCT00273312
Locations
🇨🇳

Novartis Investigative Site, Tai Chung Municipality, Taiwan

Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

Phase 4
Completed
Conditions
First Posted Date
2005-12-20
Last Posted Date
2017-02-07
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
1020
Registration Number
NCT00267176
Locations
🇩🇪

Novartis, Nuernberg, Germany

🇺🇸

Southern Illinois Clinical Research, O'Fallon, Illinois, United States

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants

First Posted Date
2005-12-20
Last Posted Date
2011-05-20
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
31
Registration Number
NCT00267150
Locations
🇩🇪

Universitätsklinikum Charité Campus Virchow Klinikum Berlin Nephrologie und Internistische Intensivmedizin, Berlin, Germany

RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency

First Posted Date
2005-12-20
Last Posted Date
2011-04-13
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
145
Registration Number
NCT00267189
Locations
🇨🇭

Novartis Investigative Site, Basel, Switzerland

🇩🇪

Novartis Investigational Site, Germany, Germany

© Copyright 2024. All Rights Reserved by MedPath